Date
- 2026 (1)
- 2025 (38)
- 2024 (86)
- 2023 (73)
- 2022 (59)
- 2021 (124)
- 2020 (107)
- 2019 (98)
- 2018 (95)
- 2017 (73)
- 2016 (12)
- 2015 (22)
- 2014 (19)
- 2013 (9)
- 2012 (8)
- 2011 (14)
- 2010 (27)
- 2009 (13)
- 2008 (5)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (3)
- 2002 (10)
- 2001 (6)
- 2000 (20)
- 1999 (9)
- 1998 (12)
- 1997 (16)
- 1996 (8)
- 1995 (3)
- 1994 (31)
- 1993 (17)
- 1992 (5)
- 1991 (86)
Sponsor content
1140 result(s) found, displaying 91 to 100
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: talazoparib tosilate.
-
Australian public assessment report (AusPar)Cibinqo (abrocitinib) has been approved for the treatment of moderate-to-severe atopic dermatitis in adults.
-
Australian public assessment report (AusPar)Tukysa (tucatinib) has been approved to be used in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2 positive unresectable or metastatic colorectal cancer.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pfizer Australia Pty Ltd - Skin-cleaning wipe, sterile.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pfizer Australia Pty Ltd - Skin-cleaning wipe, sterile.
-
Prescription medicine decision summaryLitfulo (ritlecitinib) has been approved for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. Alopecia areata is an autoimmune disease that causes hair loss.